Cytokinetics (CYTK, $67.93) was a top loser over the last three months, falling to $67.93 per share. A.I.dvisor analyzed 920 stocks in the Biotechnology Industry for the 3-month period ending April 17, 2024, and found that of them (5) exhibited an Uptrend while of them (4) demonstrated a Downtrend.